Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

By L. A. Stewart. The Lancet, 2002

1,255 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. (2005, background): “high preoperative Karnofsky performance score and younger age (1, 2).”
Genetic Pathways to Glioblastoma (2004, background): “A recent meta-analysis showed that 40% of patients with malignant glioma treated with radiotherapy and 46% treated with radiotherapy plus chemotherapy survived 1 year (1).”
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. (2003, background): “The role of chemotherapy in the treatment of malignant glioma was recently reviewed in a meta-analysis published by the GMT group (Stewart, 2002).”
Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, background): “In conjunction with surgery and medical management, radiation therapy doubles median survival to 12 mo and extends 2-yr survival to 10%, with little added benefit from conventional chemotherapies (Shapiro et al. 1989; Fine et al. 1993; DeAngelis et al. 1998; Stewart 2002).”
Long-term survival with glioblastoma multiforme. (2007, background): “Calculated on the basis of data that were provided in the concerning paper.”